of anhydrides instead of esters in the enzyme-catalyzed
acylation of alcohols in organic solvent has been less
applied and was first described by Cesti et al.5 The
reverse reaction involves the nucleophilic attack of a
carboxylic acid to an ester, and is therefore thermo-
dynamically unfavored. The utilization of cyclic anhy-
drides as acylating agents for the enzymatic esterification
is especially advantageous, because it leads to the forma-
tion of a monoester of a diacid that can be easily
separated from the unreacted alcohol by extraction with
base. For instance, Terao et al.6 have described the lipase-
catalyzed resolution of racemic alcohols in organic sol-
vents using succinic anhydride as an acylating agent.
Recently, this anhydride has also been used for the
resolution of a hydroxymethylpiperidine,7 even though
only moderate enantioselectivities were obtained. Here,
we study the enzymatic esterification of alcohol (()-
trans-1 using several commercially available cyclic an-
hydrides as acyl donors.8
An h yd r id es a s Acyla tin g Agen ts in th e
En zym a tic Resolu tion of a n In ter m ed ia te
of (-)-P a r oxetin e
Gonzalo de Gonzalo, Rosario Brieva, V´ıctor M. Sa´nchez,†
Miguel Bayod,† and Vicente Gotor*
Departamento de Quı´mica Orga´nica e Inorga´nica, Facultad
de Quı´mica, Universidad de Oviedo, 33071-Oviedo, Spain
vgs@sauron.quimica.uniovi.es
Received J anuary 29, 2003
Abstr a ct: A new chemoenzymatic method for the prepara-
tion of an intermediate of (-)-Paroxetine is reported. Cyclic
anhydrides are used as acylating agents in the lipase-
catalyzed esterification of trans-4-(4′-fluorophenyl)-3-hy-
droxymethyl-N-phenyloxycarbonylpiperidine in organic sol-
vents. The best enantioselectivities are obtained with two
different lipases from Candida antarctica. These two lipases
show opposite stereochemical preference in these processes,
so that both enantiomers can be obtained in their optically
pure forms. The (3S,4R) isomer is an intermediate for the
synthesis of (-)-Paroxetine.
In a first set of experiments, several lipases were tested
in the esterification reaction of alcohol (()-trans-1 with
2 equiv of succinic anhydride in toluene at 30 °C. Table
1 (entries 1-4) shows the results obtained with the
immobilized lipases from Candida antarctica (CAL-A,
CAL-B, and CAL-B-L2) and Pseudomonas cepacia
(PS-C). With other lipasessPseudomonas cepacia (PS),
Candida rugosa (CRL), or porcine pancreatic (PPL)sthe
unaltered starting material was recovered. CAL-A showed
the highest enantioselectivity (E ) 51, entry 1),9 and a
high reaction rate. In an attempt to optimize this
reaction, we studied the effect of other reaction param-
eters on the enantioselectivity of the esterification of (()-
trans-1 catalyzed by CAL-A. First, we studied the influ-
ence of the organic solvent. The reaction in t-BuOMe
(entry 5) was slower and less enantioselective than that
in toluene (entry 1). On the other hand, the reaction rate
was enhanced in i-Pr2O but again the enantioselectivity
was lower than in toluene. There was no reaction when
acetonitrile, acetone, or 1,4-dioxane were used. Lowering
the temperature to 15 °C in toluene (entry 6) did not
significantly affect the enantioselectivity. Additional
experiments showed that the amount of succinic anhy-
dride affects both the reaction rate and the enantio-
selectivity. As expected, the reaction rate decreased when
1 equiv of anhydride was employed (entry 7). By contrast,
the reaction rate was not significantly enhanced in the
presence of 4 equiv of anhydride (compare entries 8 and
1). In both experiments, lower enantioselectivities were
Optically pure (-)-Paroxetine 5 (Scheme 1) is a potent
and selective inhibitor of 5-hydroxytryptamine reuptake,
and is used in the treatment of a variety of human
diseases such as depression, obsessive compulsive disor-
der, and panic disorder.1 The interest of the pharmaceu-
tical industry in the preparation of this drug requires the
development of new synthetic methods suitable to be
carried out at large scale. As a part of our research on
the enzymatic preparation of optically active drugs by
chemoenzymatic methods,2 we have focused on the
resolution of N-substituted trans-4-(4′-fluophenyl)-3-hy-
droxymethylpiperidines 1, key intermediates in the
synthesis of (-)-Paroxetine. In a previous report, we
described the resolution of these intermediates via a
lipase-catalyzed acylation.3 In this procedure, the enan-
tiopure acylated product and the remaining nonacylated
alcohol are separated by chromatography after the
enzymatic reaction. Although the availability, the low
cost, and the low environmental impact of the lipase-
catalyzed resolution of the racemates are important
advantages for the large-scale production of the optically
pure Paroxetine, the need for a chromatographic separa-
tion is a major drawback for the scaling up of that
procedure.
(4) Santaniello, E.; Reza-Elahi, S.; Ferraboschi, P. Chiral Synthons
by Enzymatic Acylation and Esterification Reactions. In Topics in
Current Chemistry; Fessner, W.D., Ed.; Springer-Verlag: Berlin,
Germany, 1999; Vol. 200, pp 415-460.
The enzymatic transesterification in the resolution of
racemic alcohols is well documentated.4 However, the use
† Current address: Astur-Pharma S. A. Pol´ıgono Industrial de
Silvota, parcela 23, 33192-Llanera (Asturias), Spain.
(1) (a) Dechant, K. L.; Clissold, S. P. Drugs 1991, 41, 225. (b) Mathis,
C. A.; Gerdes, J . M.; Enas, J . D.; Whitney, J . N.; Taylor, S. E.; Zahang,
Y.; Mckenna, D. J .; Havlik, S.; Peroutka, S. J . J . Pharm. Pharmacol.
1992, 44, 801-805.
(2) Gotor, V. Org. Proc. Res. Dev. 2002, 6, 420-426.
(3) (a) De Gonzalo, G.; Brieva, R.; Sa´nchez, V. M.; Bayod, M.; Gotor,
V. J . Org. Chem. 2001, 66, 8947-8953. (b) Bayod, M.; Sa´nchez, V. M.;
de Gonzalo, G.; Brieva, R.; Gotor, V. U.S. Patent 2003/0018048 to Astur
Pharma.
(5) Bianchi, D.; Cesti, P.; Battistel, E. J . Org. Chem., 1988, 53,
5531-5534.
(6) Terao, Y.; Tsuji, K.; Murata, M.; Achiwa, K.; Nishio, T.; Wa-
tanabe, N.; Seto, K. Chem. Pharm. Bull. 1989, 37, 1653.
(7) Goswami, A.; Howell, J . M.; Hua, E. Y.; Mirfakhrae, K. D.;
Soumeillant, C. M.; Swaminathan, S.; Qian, X.; Quiroz, F.; Vu, T. C.;
Wang, X.; Zheng, B. Org. Proc. Res. Dev. 2001, 5, 415-420.
(8) Bayod, M.; Sa´nchez, V. M.; de Gonzalo, G.; Brieva, R.; Gotor, V.
ES Patent P200202916 to Astur Pharma.
(9) Chen, C. S.; Fujimoto, Y.; Girdaukas, G.; Sih, C. J . J . Am. Chem.
Soc. 1982, 104, 7294.
10.1021/jo034120b CCC: $25.00 © 2003 American Chemical Society
Published on Web 03/18/2003
J . Org. Chem. 2003, 68, 3333-3336
3333